Verastem, Inc.
NASDAQ:VSTMBiotechnology
-$0.00 today
- Market cap
- $865.72M
- Beta
- 0.27
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.97
Volume 3.97M
Average 2.58M
VSTM Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Verastem, Inc.NASDAQ: VSTM
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of $36.59M (cash outflow) fell 29.8% year over year, behind the +30.3% change in trailing-twelve-month net income. Sequentially, it rose 11.2% from the prior quarter. Over 3 fiscal years it compounded at +41.6% a year.
Context
- Net income amounted to 677.6% of revenue in FY2025, down 628.8 pp from a year earlier.
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$141.82M (-32.3%) for the fiscal year ending Dec 2026, a slowdown from the +60.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$36.59M+11.2% QoQ
- Last fiscal yearDec 2025
- -$209.47M+60.3% YoY
- LTMMar 2026
- -$193.96M+30.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -29.8% | +68.0% | +97.8 pp |
| 1 year | +60.3% | -32.3% | -92.6 pp |
| 3-year CAGR | +41.6% | -21.0% | -62.6 pp |
| 5-year CAGR | -44.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (209.47M) USD
- Year-over-year change
- -60.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (209.47M) | -60.3% |
| FY2024 | 2024-12-31 | (130.64M) | -49.5% |
| FY2023 | 2023-12-31 | (87.37M) | -18.4% |
| FY2022 | 2022-12-31 | (73.81M) | -3.7% |
| FY2021 | 2021-12-31 | (71.2M) | — |
Net Income vs competitors
How VSTM compares with its peers on the latest reported figures
- VSTM's LTM Mar 2026 net income of $193.96M is the largest of the 11 companies compared; the peer median is $76.3M.
- Its year-over-year change of +30.3% is the 3rd highest of 10, against a peer median of -6.4%.
- Net income amounts to 391.2% of revenue for VSTM, versus a peer median of 381.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $193.96M | +30.3% | +41.6% | 391.2% | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $154.1M | +1029.3% | +3264.4% | — |
| LTM Mar 2026 | $135.21M | +1.8% | +13.3% | — | |
| LTM Jun 2026 | $112.24M | +155.3% | +25.2% | 66.1% | |
| LTM Mar 2026 | $103.8M | +0.5% | -6.4% | 297.8% | |
| LTM Mar 2026 | $77.8M | -39.1% | -4.8% | 465.3% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $77.27M | -7.7% | +35.7% | — |
| LTM Mar 2026 | $75.32M | -6.4% | -12.0% | 266.9% | |
| LTM Mar 2026 | $54.44M | -11.9% | +3.5% | — | |
| LTM Jun 2024 | $54.07M | — | -15.4% | 833.1% | |
| LTM Mar 2026 | $44.76M | -8.4% | +5.8% | 8526.1% | |
| Peer median (excluding VSTM) | $76.3M | -6.4% | +4.7% | 381.5% | |
Competitors are the stored peer set for VSTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.2M) | (73.81M) | (87.37M) | (130.64M) | (209.47M) |
| Depreciation & Amortization | 72K | (36K) | 62K | 26K | 728K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.71M | 6.05M | 5.86M | 7.34M | 9.4M |
| Change in Working Capital | 584K | 3.9M | (957K) | 3.72M | 26M |
| Accounts Receivables | (277K) | 485K | 31K | (200K) | (8.81M) |
| Inventory | 0 | 0 | 0 | 0 | (1.83M) |
| Accounts Payables | 623K | 2.6M | 2.28M | (3.16M) | 8.42M |
| Other Working Capital | 238K | 816K | (3.27M) | 7.08M | 28.23M |
| Other Non-Cash Items | 9.33M | 228K | (4.06M) | 14.78M | 35.83M |
| Operating Cash Flow | (53.5M) | (63.67M) | (86.46M) | (104.77M) | (137.51M) |
| Capital Expenditures | (196K) | 0 | 0 | (28K) | 0 |
| Acquisitions (Net) | 9.33M | 0 | 0 | 0 | 0 |
| Purchases of Investments | (86.44M) | (17.82M) | (96.45M) | 0 | 0 |
| Sales of Investments | 86.73M | 84M | 52M | 60M | 29K |
| Other Investing Activities | (9.33M) | 0 | 0 | 5K | (29K) |
| Investing Cash Flow | 87K | 66.19M | (44.45M) | 59.97M | (9.62M) |
| Debt Repayment | 0 | 24.15M | 14.62M | (150K) | 32.42M |
| Common Stock Issued | 6.72M | 27.35M | 91.42M | 14.22M | 230.88M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 162K | 282K | 57K | 40.71M | 0 |
| Financing Cash Flow | 6.89M | 51.78M | 134.19M | 54.78M | 263.31M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (46.53M) | 54.3M | 3.29M | 9.98M | 116.17M |
| Free Cash Flow | (53.7M) | (63.67M) | (86.46M) | (104.8M) | (137.51M) |
Verastem, Inc.
NASDAQ:VSTM
Intrinsic Alpha fair value
Locked
Current Price
$6.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.